- Neogen reported fiscal third-quarter 2026 results in conjunction with its guidance increase and Genomics divestiture announcement.
- Neogen entered a definitive $160 million agreement to sell its global Genomics business to Zoetis.
Thursday, April 9, 2026
Neogen raises FY26 revenue guidance and agrees to sell global Genomics business to Zoetis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.